Evaluation of serum protein markers in diagnosis of hepatocellular carcinoma and carcinogenesis risk assessment in chronic liver disease patients

Essraa Adel Aly Aly Hegazy¹*, Somaia Abdellatif Eissa¹, Ashtaf Elsayed Abdel Hamid Sorour¹, Hanan Hassan Fouad², Dalia Abdel Hamid Omran³

¹Department of Medical Microbiology and Immunology, Faculty of Medicine, Cairo University, Cairo, Egypt
²Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt
³Department of Tropical Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt

ARTICLE INFO

Objective: To assess the diagnostic value of the protein markers in both cirrhotic patients on top of hepatitis C virus (HCV) and in hepatocellular carcinoma (HCC) patients on top of HCV in comparison to normal controls.

Methods: A total number of 100 subjects including HCC, cirrhotic patients on top of HCV and normal controls were subjected to serum protein markers analysis for alpha-fetoprotein, apolipoprotein A1, apolipoprotein A2, insulin like growth factor 1 and insulin like growth factor 1 receptor by western blotting technique.

Results: It was found that alpha-fetoprotein alone could not be used as a screening test while apolipoprotein A2 as a serum marker could be used as a non invasive screening test to differentiate a case of HCC from cirrhotic HCV patient. The all four markers were able to discriminate normal persons from HCC and cirrhotic HCV patients effectively.

Conclusions: We concluded that proteomics analysis being non invasive, rapid and sensitive is a novel gate that can serve in early diagnosis and screening of HCC and cirrhotic HCV patients.

Keywords: Evaluation Serum protein markers Hepatocellular carcinoma Carcinogenesis HCV

1. Introduction

Hepatitis C virus (HCV) is one of the major health problem, which leads to chronic infection of 350 million individuals in the world[1]. Hepatitis C is the most public health stress in Egypt where HCV prevalence is the highest in the world. Egypt Health Issues Survey (2015) showed that between 15 and 59 years of age, about 10% of Egyptians had been infected with HCV infection, while 7% of them have chronic active hepatitis C[2].

About 40%–60% of HCV infections result in chronic liver disease which could be complicated by hepatocellular carcinoma (HCC) via oxidative stress, insulin resistance, fibrosis, liver cirrhosis and HCV induced steatosis[3].

Unfortunately, HCC diagnosis usually is made when patients become symptomatic with liver function affection. At this late time, there is no beneficial treatment that would improve survival[3].

Liver function tests including alpha-fetoprotein are of little value in screening for liver disease as many serious liver diseases may be associated with normal levels and abnormal levels might be found in asymptomatic healthy individuals[4].

Also the use of liver biopsy as a screening method carries many risks for a hepatic patient. Studies found a great benefit for early screening of patients for HCC that gave them the option for receiving multiple treatment choices with improved clinical outcomes[5]. This leads to the idea of using non invasive
biomarkers with minimal risk and complications as proteomes analysis as a screening method for early detection of cases of HCC. With proper screening, we could save many patients and help them to preserve proper functioning liver.

2. Materials and methods

2.1. Study area

This study was conducted on a total number of 100 patients. They were divided into 3 well matched age and sex groups. Group 1 included 50 HCC patients on top of HCV. Group 2 included 30 cirrhotic patients on top of HCV. Group 3 included 20 healthy control subjects with no liver disease or a history of hepatitis virus infection. All patients were from Gastroenterology and Hepatology Department of Kasralainy Hospital and outpatient clinic.

Written informed consents were obtained from all patients before enrollment into the study. All patients and controls were subjected to the following: detailed history taking including demographic data and medical history; complete clinical and radiological examination with special emphasis on abdominal examination; laboratory investigation including serum alpha-fetoprotein, apolipoprotein A1 (Apo A1), apolipoprotein A2 (Apo A2), insulin like growth factor 1 (IGF1), insulin like growth factor 1 receptor (IGF1R) and serologic tests for hepatitis B virus, HCV, and HIV.

2.2. Sample collection

Study was done from October 2015 until May 2016. A volume of 5 mL blood was withdrawn from each patient in clear EDTA-free tubes labeled with their name and date of collection under complete aseptic conditions to separate a volume of 3 mL serum by centrifugation. The serum was divided into six aliquots to prevent repeated freezing and thawing of the same aliquot. Only clear, non-hemolyzed samples were used. Sera were stored at –80°C till processing.

2.3. Sample processing

All samples were subjected to the following: A. Protein extraction using ReadyPrep™ Protein Extraction Kit, USA and determination of protein concentration by Bradford protein assay kit, Bio Basic Inc., Canada; B. Electrophoresis and protein separation using Bio-Rad electrophoresis, USA where proteins of biological samples were separated as isolated bands; C. Western blotting using Trans-Blot, Bio-Rad, USA where transfer of protein from the gel into a polyvinylidene fluoride membrane was followed by its blocking; D. Proteins identification using primary and secondary antibodies followed by quantification using chemoluminescence; E. Result analysis by gel imaging and gel documentation system (Gel Doc XR+, Bio-Rad, USA).

We used primary antibody that specifically binds to the protein of our research interest for the purpose of purifying, detecting and measuring followed by secondary nonspecific antibodies that are used for the indirect detection of target protein. Secondary antibody provides increased sensitivity through signal amplification, elimination of cross-reactivity in detection of primary antibodies and offers greater flexibility for labeling and detection by chemoluminescence.

We confirm that the study protocol was performed according to the Helsinki declaration and approved by Cairo University Ethical committee and that informed written consent was obtained from all patients and controls.

2.4. Statistical analysis

Data were coded and entered using the statistical package SPSS version 15. Data were summarized using number and percent for qualitative variables, while mean and standard deviation was used for quantitative values which are normally distributed while median and range were used for quantitative variables which are not normally distributed.

Comparisons between groups were done using Chi-squared test for qualitative variables. Mann-Whitney test was used for quantitative values which are not normally distributed. Correlations were done to test for linear relation between variables. Receiver operating characteristic (ROC) curve was used to test the discriminating ability of each marker to discriminate between cirrhotic HCV, HCC and controls. \( P \) value less than or equal to 0.05 was considered as statistically significant.

3. Results

No statistical significance was found due to age or sex difference. All controls serum biomarkers levels were within standard universal normal range.

On comparing level of four markers among HCC and HCV cirrhotic patients versus normal levels, we found that only Apo A2 showed higher results than normal range while the other markers showed lower level than normal as shown in Figures 1 and 2.

On measuring alpha-fetoprotein in HCC patients (level ranges between 5.1 and 412.0 ng/dL), all patients showed higher level than the normal range while the other markers showed lower level than normal as shown in Figures 1 and 2.

While in cirrhotic HCV patients (level ranges between 1.5 and 164.0 ng/dL), 25% of patients showed normal level of alpha-fetoprotein (Table 1).
Upon analysis of diagnostic value of all markers to differentiate HCC patients from normal person, we found that all four markers were able to differentiate between the two cases as follows.

When Apo A1, Apo A2, IGF1, and IGF1R at cutoff levels < 112.5 mg/dL, < 53 mg/dL, < 78 ng/dL, and < 93.5 ng/dL respectively, the highest sensitive tests were Apo A1, IGF1 and IGF1R and the least sensitive was Apo A2 test (Figure 4).

**3.2. ROC curve (HCC versus controls)**

The above figure showed that all four markers could differentiate effectively between a case of HCC and a healthy subject.
3.3. ROC curve (cirrhotic HCV versus controls)

Upon analysis of diagnostic value of all markers to differentiate cirrhotic HCV patients from normal person, we found that all four markers were able to differentiate between the two cases as follows. When Apo A1, Apo A2, IGF1, and IGF1R at cutoff levels < 121.5 mg/dL, > 53 mg/dL, < 71 ng/dL and < 73 ng/dL respectively, the highest sensitive tests were IGF1 and IGF1R equally followed by Apo A1 and Apo A2 tests (Figure 5).

![ROC curve](image)

Figure 5. ROC curve (cirrhotic HCV versus controls).

The above figure showed that all four markers could differentiate effectively between a case of cirrhotic HCV and a healthy subject.

4. Discussion

In this study, alpha-fetoprotein measurement in HCC patients ranged between 5.1 and 412 ng/dL which was higher than the normal range (0–5 ng/dL) as stated by Nicoll et al.[8]. Both Lin et al.[7] and Ebrahim et al.[8] agreed with this result and recorded alpha-fetoprotein level between 6 and 390 ng/dL in HCC patients with small tumor size. Hah et al.[9] stated that one major disadvantage for the use of alpha-fetoprotein is that it can be falsely raised in patients who have active hepatitis but no evidence of HCC. This suggests that higher serum alpha-fetoprotein levels independently could not be used as a reliable marker alone to prove HCC case as approved by Ohhira et al.[10].

In our study, Apo A1 level decreased significantly in comparison to normal reference range (> 150 mg/dL). In case of HCC patients, the level ranged between 10 and 105 mg/dL with mean 52.7 mg/dL as agreed by Ehsani Ardakani et al.[11], Wang et al.[12] and Yang et al.[13] who recorded Apo A1 mean level in HCC patients as 30, 13 and 60 mg/dL, respectively. While in cirrhotic patients, Apo A1 mean level was 70.7 mg/dL which was consistent with Mustafa et al.[14] whose record was 30 mg/dL while Li et al.[15] recorded Apo A1 mean level in cirrhotic patients to reach 23 mg/dL. The above data showed that there was no marked difference in Apo A1 levels that could differentiate between cirrhotic HCV and HCC patients. From the above data, we observed that a decrease in plasma apolipoprotein and lipid levels is positively correlated with the severity of liver failure as confirmed by Li et al.[15].

The results of quantitative analysis revealed that Apo A2 protein was upregulated in the plasma of HCC to reach a range of 52–190 mg/dL with mean 130.9 mg/dL, while in case of cirrhotic patient it reached a range of 50–144 mg/dL with mean 78.9 mg/dL compared to healthy control samples normal level that ranged between 30–50 mg/dL. Oliveira et al.[16] and Seki et al.[17] agreed with our results and recorded raised Apo A2 level in HCC patients to reach 65 and 98 mg/dL, respectively. Zhang et al.[18], Petit et al.[19] and Perlemuter et al.[20] recorded Apo A2 high level to reach 160, 142 and 180 mg/dL respectively in cirrhotic patients, which agreed with our results.

In our patients, serum concentration of IGF1 showed no differences related to age nor sex as agreed by Kasprzak et al.[21] and Adamek et al.[22] who stated same results as ours. Upon recording IGF1 level in our HCC patients, it decreased significantly to reach a range of 12–67 mg/dL with a mean level 48.2 mg/dL in comparison to normal reference range (74–300 mg/dL). Kasprzak et al.[21] agreed with our results and recorded IGF1 mean level in HCC patients to reach 56 mg/dL. In case of cirrhotic patients, IGF1 level was measured and ranged between 15 and 68 mg/dL with a mean level 49 mg/dL which was lower than normal range.

In our study, IGF1R is reduced in severe liver disease to reach below the normal range in adult which is 93–174 ng/mL. In cases of HCC, it was recorded to be 17–53 mg/dL with mean level 32.6 mg/dL which was agreed by Lin et al.[23] who stated IGF1R level in his study to reach 33 ng/dL. In cases of cirrhotic patients, the level was decreased ranging between 17 and 53 ng/dL with a mean level 35.1 mg/dL which was agreed by Yang et al.[13] and Kasprzak et al.[21] who recorded the level to be 16 and 63 mg/dL, respectively.

In our study, Apo A1 had the ability to differentiate between a case of HCC and cirrhotic HCV patient at cutoff value < 127 mg/dL with sensitivity 7.13%, specificity 94.20%, PPV 90%, NPV 90%, and TA 92.30%. Both Lin et al.[7] and Adamek et al.[22] stated similar results to us and recorded that Apo A1 sensitivity was 45% and specificity was 56% at cutoff level of 46 mg/dL.

In our study, Apo A2 can discriminate a case of HCC from cirrhotic HCV patient at cutoff value > 127 mg/dL with sensitivity 7.13%, specificity 90.6%, PPV 92.7%, NPV 67.4% and TA 79.7%. Liu et al.[24] recorded results similar to us and stated that Apo A2 at cutoff level > 107 mg/dL with sensitivity 13% and specificity 96% to differentiate a case of HCC from cirrhotic HCV patient.

Our study showed that IGF1 and IGF1R were not able to differentiate a case of HCC from cirrhotic HCV which was agreed by Jiang et al.[25] who denied the diagnostic value of IGF1 and IGF1R in ruling out a case of HCC.

In our study, alpha-fetoprotein at cutoff value > 48 ng/dL can differentiate a case of HCC from cirrhotic HCV with sensitivity 69.2%, specificity 71.9%, PPV 80%, NPV 95% and TA 70.2%. Ebrahim et al.[8] agreed with our results and stated that an alpha-fetoprotein value above 400 ng/dL has been considered to be diagnostic for HCC with sensitivity 70% and specificity 65%.

We thereby concluded that the use of Apo A1 and Apo A2 had the ability to differentiate between a case of HCC and cirrhotic HCV patient while alpha-fetoprotein, IGF1 and IGF1R have no clear role
to differentiate the two cases. Also we observed that all our tested markers had the ability to discriminate a normal healthy person from HCC and cirrhotic HCV patients.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

The authors wish to thank Professor Dr Nadia Hafez, Head of Department Medical Microbiology and Immunology, Faculty of Medicine, Cairo University for a pre-review of this article as well as her constructive criticisms. Special thanks go to Mrs. Mona Ezzat, the former Chief Technologist of the Department of Medical Biochemistry, for her assistance during our work in western blotting technique. Our project was funded by Cairo University and Arab academy for science, technology and maritime transport cooperation program grant number 3714677 year 2015.

References

[1] Arshad AM, Ashfaq UA. Epidemiology of hepatitis c infection in Pakistan: current estimate and major risk factors. Crit Rev Eukaryot Gene Expr 2017; 27(1): 63-77.
[2] Shiha G, Seif S, Eldesoky A, Elbasiony M, Soliman R, Metwally A, et al. A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C. Hepatol Int 2017; 11(3): 286-91.
[3] Pok S, Vohra H, Wehbe C, Bam V, Arfianti E, Dan YY, et al. Deriving and testing of dysplastic murine hepatocytes: a new platform in liver cancer research. Exp Cell Res 2017; 356: 48-56.
[4] Zhang JL, Lin HF, Wang XY, Zhang DQ, Chen XJ, Zhuang YG, et al. Predictive value of microRNA-143 in evaluating the prognosis of patients with hepatocellular carcinoma. Cancer Biomark 2017; 19(3): 257-62.
[5] Hendy OM, Elsabaawy MM, Aref MM, Khalaf FM, Oda AM, El Shafty HM. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease. APMIS 2017; 125(7): 607-13.
[6] Nicol D, McPhee SJ, Pignone M, Lu CM. Pocket guide to diagnostic tests. 5th ed. New York: McGraw-Hill; 2008.
[7] Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife 2014; 3: e04766.
[8] Ebrahim AH, Alalawi Z, Miranda L, Rakshshanda R, Dahlbeck S, Nguyen D, et al. Galectins in cancer: carcinogenesis, diagnosis and therapy. Ann Transl Med 2014; 2(9): 88.
[9] Hah N, Sherman MH, Yu RT, Downes M, Evans RM. Targeting transcriptional and epigenetic reprogramming in stromal cells in fibrosis and cancer. Cold Spring Harb Symp Quant Biol 2015; 80: 249-55.
[10] Ohhira M, Fujimoto Y, Matsumoto A, Ohtake T, Ono M, Kohgo Y. Hepatocellular carcinoma associated with alcoholic liver disease: a clinicopathological study and genetic polymorphism of aldehyde dehydrogenase 2. Alcohol Clin Exp Res 1996; 20: 378A-82A.
[11] Elsani Arakdani MJ, Safaei A, Arefi Oskouie A, Haghiparast H, Haghisali M, Mohaghegh Shalmani H, et al. Evaluation of liver cirrhosis and hepatocellular carcinoma using Protein-Protein Interaction Networks. Gastroenterol Hepatol Bed Bench 2016; 9: 514-22.
[12] Wang Y, Hao J, Liu X, Wang H, Zeng X, Yang J, et al. The mechanism of apolipoprotein A1 down-regulated by hepatitis C virus. Lipids Health Dis 2016; 15: 64.
[13] Yang Z, Cappello T, Wang L. Emerging role of microRNAs in lipid metabolism. Acta Pharm Sin B 2015; 5(2): 145-50.
[14] Mustafa MG, Petersen JR, Ju H, Cicales L, Snyder N, Haidacher SJ, et al. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients. Mol Cell Proteomics 2013; 12(12): 3640-52.
[15] Li Y, Kakinami C, Li Q, Yang B, Li H. Human apolipoprotein A-I is associated with dengue virus and enhances virus infection through SR-BI. PLoS One 2013; 8(7): e70390.
[16] Oliveira KG, Malta FM, Nastri AC, Widman A, Faria PL, Santana RA, et al. Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3. Med Microbiol Immunol 2016; 205(2): 111-7.
[17] Seki N, Sugita T, Aida Y, Itagaki M, Ishiguro H, Sutoh S, et al. Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2. Hepatol Int 2014; 8(4): 550-9.
[18] Zhang X, Zhang Z, Dai F, Shi B, Chen L, Zhang X, et al. Comparison of circulating, hepatocyte specific messenger RNA and microRNA as biomarkers for chronic hepatitis B and C. PLoS One 2014; 9(3): e92112.
[19] Petit JM, Jooste V, Duviillard L, Minello A, Texier V, Galland F, et al. Apolipoprotein-AI concentrations are associated with liver steatosis in patients with chronic hepatitis C. Dis Sci 2007; 52(12): 3431-4.
[20] Perlemuter G, Sabile A, Letteron P, Vona G, Toplicio A, Chrétien Y, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2012; 26(2): 185-94.
[21] Kasprzak A, Adamek A, Przybylszewska W, Pyda P, Szmeja J, Seraszek-Jaros A, et al. Insulin-like growth factor-1 mRNA isoforms and insulin-like growth factor-1 receptor mRNA expression in chronic hepatitis C. World J Gastroenterol 2015; 21(13): 3867-75.
[22] Adamek A, Kasprzak A, Mikosi H, Przybylszewska W, Seraszek-Jaros A, Czaja A, et al. The insulin-like growth factor-1 and expression of its binding protein 3 in chronic hepatitis C and hepatocellular carcinoma. Oncol Rep 2013; 30(3): 1337-45.
[23] Lin SB, Zhou L, Liang ZY, Zhou WX, Jin Y. Expression of GRK2 and IGFIR in hepatocellular carcinoma: clinicopathological and prognostic significance. J Clin Pathol 2017; doi: 10.1136/jclinpath-2016-203998.
[24] Liu Y, Sogawa K, Sunaga M, Umemura H, Sato M, Kazami T, et al. Increased concentrations of apo A-I and apo A-II fragments in the serum of patients with hepatocellular carcinoma by magnetic beads-assisted MALDI-TOF mass spectrometry. Am J Clin Pathol 2014; 141(1): 52-61.
[25] Jiang ZH, Zhang ZY, He M, Qin J, Wang Q, Wei X, et al. [The screening and identification of apolipoprotein A-II from serum differential proteins in hepatocellular carcinoma patients]. Zhonghua Gan Zang Bing Za Zhi 2010; 18(6): 445-9. Chinese.